Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 216 publications
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.
Journal: Cardiology and therapy
Published: April 03, 2026
Identification of prognostic biomarkers in a large cohort of patients with LGMD R2.
Journal: Journal of neurology
Published: March 10, 2026
Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management.
Journal: Human gene therapy
Published: February 13, 2026
Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.
Journal: Neurology and therapy
Published: September 10, 2025
A prospective observational study assessing the functional disease progression of LGMDR4, betasarcoglycan-related limb girdle muscular dystrophy.
Journal: Journal of neuromuscular diseases
Published: May 13, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.
Journal: JAMA neurology
Published: May 12, 2025
Gross motor delays in infants and young boys with Duchenne muscular dystrophy.
Journal: Journal of neuromuscular diseases
Published: February 20, 2025
Limb-Girdle Muscular Dystrophy Scientific Workshop: A Multistakeholder Discussion Focused on Charting the Path Forward for Drug Development.
Journal: Neurology. Clinical practice
Published: January 21, 2025
Modeling of Dysferlinopathy (LGMDR2) Progression: A Longitudinal Fat Fraction Analysis.
Journal: Neurology. Genetics
Published: December 20, 2024
High-Density Lipoprotein-Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin-Deficient Limb-Girdle Muscular Dystrophy Type R2.
Journal: Journal of cachexia, sarcopenia and muscle
Published: November 27, 2024
Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy.
Journal: Journal of neuromuscular diseases
Published: April 12, 2024
Last Updated: 09/26/2026